Abstract
The involvement of chemokines and chemokine receptors in a great variety of pathological indications underscores their utility as therapeutic targets. In general, chemokine-mediated migration and signaling requires three distinct interactions: self-association, glycosaminoglycan (GAG) binding and activation of G proteincoupled receptors (GPCRs). Solution-state nuclear magnetic resonance (NMR) spectroscopy has long been used to determine the apo structure of chemokines and monitor complex formation; however, it has never contributed directly to drug discovery efforts that are traditionally focused on the previously inaccessible chemokine receptors. Our lab recently demonstrated that NMR structures can be successfully utilized to direct drug discovery against chemokines. The ease of collecting chemokine structural data coupled with the increased efficiency of structure-based drug discovery campaigns makes chemokinedirected therapies particularly attractive. In addition, recent advances in sample preparation, spectrometer hardware and pulse program development are allowing researchers to examine interactions with previously inaccessible partners - including full-length chemokine receptors. These developments will facilitate exploration of novel ways to modulate chemokine activity using structure-guided drug discovery.
Original language | English (US) |
---|---|
Pages (from-to) | e293-e299 |
Journal | Drug Discovery Today: Technologies |
Volume | 9 |
Issue number | 4 |
DOIs | |
State | Published - 2012 |
Funding
JJZ is funded by a Postdoctoral Fellowship from the Medical College of Wisconsin Cancer Center and BFV is supported by National Institute of Health grants AI058072 , GM097381 and AI063325 .
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery